Literature DB >> 20702622

Stably expressed APOBEC3F has negligible antiviral activity.

Eri Miyagi1, Charles R Brown, Sandrine Opi, Mohammad Khan, Ritu Goila-Gaur, Sandra Kao, Robert C Walker, Vanessa Hirsch, Klaus Strebel.   

Abstract

APOBEC3F (A3F) is a member of the family of cytidine deaminases that is often coexpressed with APOBEC3G (A3G) in cells susceptible to HIV infection. A3F has been shown to have strong antiviral activity in transient-expression studies, and together with A3G, it is considered the most potent cytidine deaminase targeting HIV. Previous analyses suggested that the antiviral properties of A3F can be dissociated from its catalytic deaminase activity. We were able to confirm the deaminase-independent antiviral activity of exogenously expressed A3F; however, we also noted that exogenous expression was associated with very high A3F mRNA and protein levels. In analogy to our previous study of A3G, we produced stable HeLa cell lines constitutively expressing wild-type or deaminase-defective A3F at levels that were more in line with the levels of endogenous A3F in H9 cells. A3F expressed in stable HeLa cells was packaged into Vif-deficient viral particles with an efficiency similar to that of A3G and was properly targeted to the viral nucleoprotein complex. Surprisingly, however, neither wild-type nor deaminase-defective A3F inhibited HIV-1 infectivity. These results imply that the antiviral activity of endogenous A3F is negligible compared to that of A3G.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20702622      PMCID: PMC2953157          DOI: 10.1128/JVI.01249-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  58 in total

1.  A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins.

Authors:  Heather L Wiegand; Brian P Doehle; Hal P Bogerd; Bryan R Cullen
Journal:  EMBO J       Date:  2004-05-20       Impact factor: 11.598

2.  Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome.

Authors:  Qin Yu; Renate König; Satish Pillai; Kristopher Chiles; Mary Kearney; Sarah Palmer; Douglas Richman; John M Coffin; Nathaniel R Landau
Journal:  Nat Struct Mol Biol       Date:  2004-04-18       Impact factor: 15.369

3.  Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.

Authors:  A Adachi; H E Gendelman; S Koenig; T Folks; R Willey; A Rabson; M A Martin
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

4.  Cytoskeleton association and virion incorporation of the human immunodeficiency virus type 1 Vif protein.

Authors:  M K Karczewski; K Strebel
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

5.  Selection, recombination, and G----A hypermutation of human immunodeficiency virus type 1 genomes.

Authors:  J P Vartanian; A Meyerhans; B Asjö; S Wain-Hobson
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

6.  Reverse transcriptase and substrate dependence of the RNA hypermutagenesis reaction.

Authors:  M A Martínez; M Sala; J P Vartanian; S Wain-Hobson
Journal:  Nucleic Acids Res       Date:  1995-07-25       Impact factor: 16.971

7.  The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity.

Authors:  Sandra Kao; Mohammad A Khan; Eri Miyagi; Ron Plishka; Alicia Buckler-White; Klaus Strebel
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

8.  APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo.

Authors:  Mark T Liddament; William L Brown; April J Schumacher; Reuben S Harris
Journal:  Curr Biol       Date:  2004-08-10       Impact factor: 10.834

9.  Complementation of vif-defective human immunodeficiency virus type 1 by primate, but not nonprimate, lentivirus vif genes.

Authors:  J H Simon; T E Southerling; J C Peterson; B E Meyer; M H Malim
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103

10.  Cytidine deamination of retroviral DNA by diverse APOBEC proteins.

Authors:  Kate N Bishop; Rebecca K Holmes; Ann M Sheehy; Nicholas O Davidson; Soo-Jin Cho; Michael H Malim
Journal:  Curr Biol       Date:  2004-08-10       Impact factor: 10.834

View more
  32 in total

1.  Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1.

Authors:  Judd F Hultquist; Joy A Lengyel; Eric W Refsland; Rebecca S LaRue; Lela Lackey; William L Brown; Reuben S Harris
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

Review 2.  Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all.

Authors:  Belete A Desimmie; Krista A Delviks-Frankenberrry; Ryan C Burdick; DongFei Qi; Taisuke Izumi; Vinay K Pathak
Journal:  J Mol Biol       Date:  2013-11-02       Impact factor: 5.469

3.  The host restriction factor APOBEC3G and retroviral Vif protein coevolve due to ongoing genetic conflict.

Authors:  Alex A Compton; Vanessa M Hirsch; Michael Emerman
Journal:  Cell Host Microbe       Date:  2012-01-19       Impact factor: 21.023

4.  Catalytic activity of APOBEC3F is required for efficient restriction of Vif-deficient human immunodeficiency virus.

Authors:  John S Albin; William L Brown; Reuben S Harris
Journal:  Virology       Date:  2013-12-20       Impact factor: 3.616

5.  Analysis of the N-terminal positively charged residues of the simian immunodeficiency virus Vif reveals a critical amino acid required for the antagonism of rhesus APOBEC3D, G, and H.

Authors:  Kimberly Schmitt; Miki Katuwal; Yaqiong Wang; Cicy Li; Edward B Stephens
Journal:  Virology       Date:  2013-12-05       Impact factor: 3.616

6.  Long-term passage of Vif-null HIV-1 in CD4+ T cells expressing sub-lethal levels of APOBEC proteins fails to develop APOBEC resistance.

Authors:  Eri Miyagi; Sandra Kao; Miyoshi Fumitaka; Alicia Buckler-White; Ron Plishka; Klaus Strebel
Journal:  Virology       Date:  2017-01-25       Impact factor: 3.616

7.  APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and macrophages.

Authors:  Chawaree Chaipan; Jessica L Smith; Wei-Shau Hu; Vinay K Pathak
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103

8.  IFN-α treatment inhibits acute Friend retrovirus replication primarily through the antiviral effector molecule Apobec3.

Authors:  Michael S Harper; Bradley S Barrett; Diana S Smith; Sam X Li; Kathrin Gibbert; Ulf Dittmer; Kim J Hasenkrug; Mario L Santiago
Journal:  J Immunol       Date:  2013-01-11       Impact factor: 5.422

9.  1.92 Angstrom Zinc-Free APOBEC3F Catalytic Domain Crystal Structure.

Authors:  Nadine M Shaban; Ke Shi; Ming Li; Hideki Aihara; Reuben S Harris
Journal:  J Mol Biol       Date:  2016-04-30       Impact factor: 5.469

10.  Correlation of APOBEC3 in tumor tissues with clinico-pathological features and survival from hepatocellular carcinoma after curative hepatectomy.

Authors:  Zongguo Yang; Yunfei Lu; Qingnian Xu; Liping Zhuang; Bozong Tang; Xiaorong Chen
Journal:  Int J Clin Exp Med       Date:  2015-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.